Collagen-Binding Fusion Proteins for Bone Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, particularly those involving parathyroid hormone (PTH) and its analogs, face challenges in delivery and efficacy, necessitating improved methods to enhance bone growth and density.
Innovation Solution
Development of collagen-binding polypeptide segments linked to PTH/PTHrP receptor agonists or antagonists, which form fusion proteins that target bone tissue, providing enhanced bioactivity and prolonged action by binding to collagen, thereby promoting bone growth and density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional PTH administration is used, then bone growth is promoted, but the duration of action is short requiring frequent dosing
Solution Approach 1:
The patent merges PTH with a collagen-binding domain to create a fusion protein. This combination allows the PTH molecule to bind to collagen in bone tissue, thereby prolonging its residence time and duration of action at the target site, reducing the need for frequent dosing
Solution Approach 2:
The collagen-binding domain acts as an intermediary that mediates between the PTH molecule and the bone tissue. By binding to collagen, this intermediary component anchors the PTH at the target site, extending its biological half-life and sustained efficacy
2Reliability
If PTH is administered systemically, then bone growth is promoted, but the bioactivity is reduced compared to local administration
Solution Approach 1:
The fusion protein exhibits local quality by having different functional domains: the PTH portion provides systemic circulation capability while the collagen-binding domain provides localized targeting to bone tissue. This allows the single molecule to achieve both systemic delivery and localized high-concentration effect at the bone site
3Manufacturing precision
If collagen-binding fusion proteins are used, then bone mineral density increases, but the protein structure becomes more complex
Solution Approach 1:
The invention creates a composite protein structure by fusing PTH with a collagen-binding domain. This composite molecule combines the bone-forming activity of PTH with the tissue-targeting capability of the collagen-binding domain, achieving enhanced bone mineral density through a single integrated therapeutic agent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen-binding fusion proteins demonstrate increased bone mineral density and prolonged efficacy compared to traditional PTH administration, with potential for less frequent dosing and sustained effects, effectively addressing the limitations of existing treatments.
Implementation Method 1
a collagen-binding polypeptide segment linked to a PTH/PTHrP receptor agonist polypeptide segment
Data Source
AI summary
Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.